Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Regenerative Medicine
  4. Strategies for neurotrophin-3 and chondroitinase ABC release from freeze-cast chitosan–alginate nerve-guidance scaffolds

Strategies for neurotrophin-3 and chondroitinase ABC release from freeze-cast chitosan–alginate nerve-guidance scaffolds

J Tissue Eng Regen Med, 2017 · DOI: 10.1002/term.1912 · Published: January 1, 2017

Regenerative MedicineBiomedical

Simple Explanation

This study explores the use of special scaffolds to help nerves regrow after spinal cord injuries. These scaffolds are designed to release helpful proteins, specifically neurotrophin-3 (NT-3) and chondroitinase ABC (chABC), which can encourage nerve regeneration. The scaffolds are made from chitosan and alginate, materials that are compatible with the body. The researchers tested how well these scaffolds could release NT-3 and chABC over time and whether these released proteins could still stimulate nerve growth. The results showed that the scaffolds could release both NT-3 and chABC for several weeks, and these proteins remained active, promoting nerve growth in lab tests. This suggests that these scaffolds could be a promising tool for treating spinal cord injuries.

Study Duration
8 weeks
Participants
E10 chick embryos
Evidence Level
In vitro study

Key Findings

  • 1
    NT-3 was released from the C–A scaffolds for 8 weeks in vitro, while chABC was released for up to 7 weeks.
  • 2
    Low total percentages of protein released from the scaffolds over this time period were attributed to limitation of diffusion by the interpenetrating polymer network matrix of the scaffold walls.
  • 3
    NT-3 and chABC released from the scaffolds retained bioactivity, as determined by a neurite outgrowth assay, and the promotion of neurite growth across an inhibitory barrier of chondroitin sulphate proteoglycans.

Research Summary

This study evaluated chitosan–alginate (C–A) scaffolds in vitro for their ability to release neurotrophin-3 (NT-3) and chondroitinase ABC (chABC) in a controlled manner to augment nerve growth across a spinal cord injury lesion. NT-3 was released from the C–A scaffolds for 8 weeks in vitro, while chABC was released for up to 7 weeks, with the released proteins retaining bioactivity, as demonstrated by a neurite outgrowth assay. The study demonstrates the potential of multifunctional scaffolds for enhancing axonal regeneration through growth-inhibiting glial scars via the sustained release of chABC and NT-3.

Practical Implications

Spinal Cord Injury Treatment

The scaffolds could be used to deliver therapeutic proteins to the injury site, promoting nerve regeneration and functional recovery.

Localized Drug Delivery

The scaffold-based delivery system can provide sustained release of therapeutic proteins, reducing the need for frequent injections or systemic administration.

Glial Scar Inhibition

The release of chABC from the scaffolds can help to degrade CSPGs, which are inhibitory molecules found in glial scars, allowing for enhanced axonal growth.

Study Limitations

  • 1
    [object Object]
  • 2
    [object Object]
  • 3
    [object Object]

Your Feedback

Was this summary helpful?

Back to Regenerative Medicine